These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7101244)

  • 1. Thrombin activation rate constant: one-stage chromogenic assay for the extrinsic system.
    Baughman DJ; Lytwyn A
    Thromb Res; 1982 Apr; 26(1):1-12. PubMed ID: 7101244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sera on thrombin activation rate constants: a one-stage assay for the extrinsic system.
    Baughman DJ; Lytwyn A
    Ann N Y Acad Sci; 1981; 370():822-35. PubMed ID: 6168232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrinsic-pathway enzyme-linked coagulation assay (EP-ELCA). A clot-based alternative to prothrombin time for measurement of extrinsic pathway factors in plasma.
    Doellgast GJ; Triscott MX; Buss DH; West J
    Clin Chem; 1988 Feb; 34(2):294-9. PubMed ID: 2830053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extrinsic coagulation activity assay.
    Stief TW; Wieczerzak A; Renz H
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):303-18. PubMed ID: 18586682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme-linked coagulation assay. II. A sensitive assay for tissue factor and factors II, VII, and X.
    Doellgast GJ; Rothberger H
    Anal Biochem; 1986 Jan; 152(1):199-207. PubMed ID: 3006542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogenic substrate spectrophotometric assays for the measurement of clotting function.
    Aiyappa PA
    Ann N Y Acad Sci; 1981; 370():812-21. PubMed ID: 6943978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests.
    Duncan A; Bowie EJ; Owen CA; Fass DN
    Clin Chem; 1985 Jun; 31(6):853-5. PubMed ID: 3995763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies.
    Francis CW; Malone JE; Marder VJ
    Am J Clin Pathol; 1985 Dec; 84(6):724-9. PubMed ID: 4072967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time.
    Nilsson CU; Strandberg K; Reinstrup P
    Scand J Clin Lab Invest; 2018 Sep; 78(5):358-364. PubMed ID: 29792060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amidolytic assay for procoagulant activity of lymphoid and tumor cells.
    Lando PA; Biazak CE; Edgington TS
    J Immunol Methods; 1986 May; 89(1):131-9. PubMed ID: 3701069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a fully automated chromogenic method for prothrombin time compared with a conventional coagulation method.
    Tripodi A; Mannucci PM
    Clin Chem; 1984 Aug; 30(8):1392-5. PubMed ID: 6744595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
    Welsch DJ; Novotny WF; Wun TC
    Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time.
    Dati F; Barthels M; Conard J; Flückiger J; Girolami A; Hänseler E; Huber J; Keller F; Kolde HJ; Müller-Berghaus G
    Thromb Haemost; 1987 Oct; 58(3):856-65. PubMed ID: 3433249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
    Chmielewska J; Latallo ZS
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
    van Dieijen-Visser MP; van Wersch J; Brombacher PJ; Rosing J; Hemker HC; van Dieijen G
    Haemostasis; 1982; 12(3):241-55. PubMed ID: 7141303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombokinetic studies in normal and factor VIII-deficient canine plasmas.
    Johnstone IB
    Can J Comp Med; 1983 Apr; 47(2):157-62. PubMed ID: 6603892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods.
    Houbouyan L; Padilla A; Gray E; Longstaff C; Barrowcliffe TW
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):24-30. PubMed ID: 8845459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.
    Testa S; Morstabilini G; Fattorini A; Galli L; Denti N; D'Angelo A
    Haematologica; 2002 Dec; 87(12):1265-73. PubMed ID: 12495900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.